Fusion Pharmaceuticals to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference
Fusion Pharmaceuticals (Nasdaq: FUSN) announced its participation in the "Hot Topic - Radiopharmaceuticals" panel at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021, at 4:05 PM EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Fusion Pharmaceuticals (Nasdaq: FUSN) announced its participation in the "Hot Topic - Radiopharmaceuticals" panel at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021, at 4:05 PM EDT. CEO John Valliant, Ph.D., will represent the company. Fusion specializes in developing precision radiopharmaceuticals, utilizing its proprietary Fast-Clear™ linker technology to target tumors selectively. Its lead program, FPI-1434, is in Phase 1 trials, supported by collaborations with AstraZeneca and Merck.
Details
News Market Reaction – FUSN
The recorded move for FUSN in the trading session of this news was -1.70%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAMILTON, ON and BOSTON, Aug. 5, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in the "Hot Topic - Radiopharmaceuticals" panel discussion at the 2021 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 11, 2021 at 4:05pm EDT. Participating in the panel on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.
About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear™ linker technology, Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966 targeting the fibroblast growth factor receptor 3 (FGFR3) and FPI-2059, a small molecule acquired from Ipsen, targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop up to three novel targeted alpha therapies (TATs) and explore up to five combination programs between Fusion's TATs and AstraZeneca's DNA Damage Repair Inhibitors (DDRis) and immuno-oncology agents. Fusion also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R.
View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-participate-in-the-2021-wedbush-pacgrow-healthcare-virtual-conference-301349762.html
SOURCE Fusion Pharmaceuticals Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.